Israel Englander’s Syndax Pharmaceuticals SNDX Stock Holding History

Israel Englander’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$1.05M	–	6334
2025 Q4	$1.05M	Buy	+50,000	New	+$872K	﹤0.01%	4454
2023 Q4	–	Sell	-260,000	Closed	-$3.78M	–	6503
2023 Q3	$3.78M	Buy	+260,000	New	+$4.92M	﹤0.01%	2978
2020 Q1	–	Sell	-100,000	Closed	-$878K	–	4431
2019 Q4	$878K	Sell	100,000 -100,000	-50%	-$734K	﹤0.01%	3063
2019 Q3	$1.49M	Buy	+200,000	New	+$1.82M	﹤0.01%	2630
2019 Q1	–	Sell	-300,000	Closed	-$1.33M	–	4302
2018 Q4	$1.33M	Sell	300,000 -14,900	-5%	-$81.7K	﹤0.01%	2441
2018 Q3	$2.54M	Buy	+314,900	New	+$2.24M	﹤0.01%	2270

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Israel Englander's SNDX Position: Q2 2026 in Review

Israel Englander increased its Syndax Pharmaceuticals (SNDX) stake by 929% in Q2 2026, buying an estimated $38.6M and bringing the position to 2,053,960 shares worth $44.9M. The position accounts for 0.02% of the portfolio, ranked #966.

Israel Englander first reported a position in SNDX in Q1 2016 and has held it in 38 quarters since. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Israel Englander held 2,053,960 shares of Syndax Pharmaceuticals worth $44.9M as of Q2 2026.
Israel Englander bought 1,854,436 Syndax Pharmaceuticals shares in Q2 2026, an estimated $38.6M.
Syndax Pharmaceuticals made up 0.02% of Israel Englander's portfolio in Q2 2026, its #966 holding.
Israel Englander first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 38 quarters since.
240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.